Kodiak Sciences Inc (NASDAQ:KOD)
| Market Cap | 5.63B+468.8% |
| Revenue (ttm) | 0 |
| Net Income | -241.99M-21.1% |
| EPS | -4.19-10.3% |
| Shares Out | 62.58M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 38,398,805 |
| Open | 61.28 |
| Previous Close | 32.35 |
| Day's Range | 60.50 - 95.77 |
| 52-Week Range | 10.94 - 95.77 |
| Beta | 2.18 |
| Analysts | Buy |
| Price Target | 76.25(-15.20%) |
| Earnings Date | Nov 12, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About KOD
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$KOD stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in KOD holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by KOD's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
KOD Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New KOD patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to KOD from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in KOD
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $48.19M |
| XBIState Street SPDR S&P Biotech ETF | $43.39M |
| IWMiShares Russell 2000 ETF | $33.57M |
| VXFVanguard Extended Market ETF | $17.85M |
| IBBiShares Biotechnology ETF | $14.48M |
| IWOiShares Russell 2000 Growth ETF | $12.34M |
Estimated from each fund’s disclosed top holdings × AUM
KOD Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from KOD’s recent data — informational, not investment advice